<DOC>
	<DOCNO>NCT00914758</DOCNO>
	<brief_summary>People multiple sclerosis ( MS ) often experience problem cognitive functioning , debilitate interfere daily functioning . However , research show MS disease modify agent success treat cognitive problem . The main purpose research study investigate well two medicine ( alemtuzumab ( Campath® ) interferon beta-1a ( Rebif® ) ) work treat MS-related cognitive problem ( e.g. , attention , memory , speed thinking ) . Participants enrol assessed prior first study-related medication dose re-assessed throughout treatment . It expect participant take Campath® demonstrate relative stability cognitive functioning relative take Rebif® . Specifically , cognitive performance Rebif® participant decline somewhat time , cognitive performance Campath® participant remain stable .</brief_summary>
	<brief_title>Comparison Campath Rebif Treatment Cognition Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>The current use neuropsychological evaluation capable detect broad range cognitive difficulty associate relapse remit MS ( RRMS ) . It sub-study investigation already underway , call Care-MS II , participant diagnose RRMS treat either Campath® Rebif® . We observe participant already assign one two study arm Care-MS II compare cognitive functioning time take Campath® take Rebif® . We also compare change cognitive functioning active group match control group . This help control practice effect help establish whether either medication help truly stabilize cognitive decline ( i.e. , relative non-MS control ) . We obtain neurocognitive data baseline ( prior first study dose Campath® Rebif® ) , 12 month ( second dose Campath® participant ) , 14 month ( 2 month second dose Campath® participant ) , 24 month ( prior third dose Campath® participant ) , 26 month ( 2 month third dose Campath® participant ) . The neurocognitive battery include gold-standard traditional neuropsychology measure well newer , validate computerized measure capable detecting change attention process speed often miss traditional measure . Since participant Care-MS II also MRI data baseline , 1 year , 2 year , cognitive finding correlate MRI data analyze post-hoc , exploratory manner participant MS . Hypotheses include : - 1 : Participants take Campath® demonstrate relative stability cognitive functioning relative take Rebif® . Specifically , cognitive performance Rebif® participant decline somewhat time , cognitive performance Campath® participant remain stable . - 2 : Participants take Campath® demonstrate similar cognitive change ( i.e. , change score 2 year ) normal , matched control . - 3 : Participants take Rebif® demonstrate great cognitive change ( i.e. , change score 2 year ) compare normal , matched control . - 4 : Cognitive stability Campath® participant correlate stability MRI parameter . - 5 : Cognitive change Rebif® participant correlate great activity MRI parameter .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosis relapse remit MS enrollment CareMS II trial NonMS control must neurologically healthy ( respect condition impact CNS functioning ) . Participants must age 25 50 . Corrected vision subject must worse 20/50 . Participants must least 10 year education . Participants must capable write press button computer mouse . Participants must capable understand follow test instruction . Participants history head injury , seizure , neurological condition involve central nervous system ( MS MS group ) . Participants upper extremity dysfunction prohibits use computer mouse . Participants colorblind . Participants history psychosis severe mental illness . Participants current alcohol/substance abuse . Participants take medication potential adverse CNS effect</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>cognition</keyword>
	<keyword>cognitive functioning</keyword>
	<keyword>Campath</keyword>
	<keyword>Rebif</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>interferon</keyword>
</DOC>